ATE:CA:TSX-Antibe Therapeutics Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 4.58

Change

-0.02 (-0.43)%

Market Cap

CAD 0.21B

Volume

0.13M

Average Target Price

CAD 15.00 (+227.51%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AUP:CA Aurinia Pharmaceuticals Inc

-0.28 (-1.75%)

CAD2.04B N/A N/A
TRIL:CA Trillium Therapeutics Inc

+0.17 (+1.34%)

CAD1.30B 1.80 N/A
APS:CA Aptose Biosciences Inc

+0.12 (+1.88%)

CAD0.57B N/A N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
BLU:CA BELLUS Health Inc

+0.16 (+2.91%)

CAD0.43B N/A N/A
MDNA:CA Medicenna Therapeutics Corp

+0.06 (+1.20%)

CAD0.27B 5.40 N/A
IMV:CA IMV Inc

+0.04 (+1.16%)

CAD0.23B -99,999.99 N/A
ONC:CA Oncolytics Biotech Inc

-0.11 (-2.77%)

CAD0.21B N/A N/A
RVX:CA Resverlogix Corp

-0.01 (-1.14%)

CAD0.21B 62.86 26.37
FRX:CA Fennec Pharmaceuticals Inc

N/A

CAD0.20B 30.20 N/A

ETFs Containing ATE:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.54% 61% D- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.54% 61% D- 73% C
Trailing 12 Months  
Capital Gain -33.62% 26% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.62% 26% F 2% F
Trailing 5 Years  
Capital Gain 336.19% 100% A+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 336.19% 100% A+ 95% A
Average Annual (5 Year Horizon)  
Capital Gain 52.01% 63% D 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.01% 63% D 96% A
Risk Return Profile  
Volatility (Standard Deviation) 97.01% 42% F 6% F
Risk Adjusted Return 53.62% 68% D+ 71% C-
Market Capitalization 0.21B 60% D- 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 12.38 18% F 6% F
Price / Cash Flow Ratio -17.54 70% C- 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -216.96% 13% F 3% F
Return on Invested Capital -223.21% 5% F 1% F
Return on Assets -76.38% 20% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.50 75% C 64% D
Short Percent N/A N/A N/A N/A N/A
Beta 0.12 82% B- 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.